Bodal Chemicals Q2 FY27: Net Profit Surges 1259% to ₹81 Crore on Strong Revenue Growth
Bodal Chemicals reported a 1,259% YoY surge in Q2 FY27 net profit to ₹81 crore on ₹884 crore revenue. H1 FY27 consolidated net profit reached ₹112 crore. The company targets over ₹3,000 crore revenue for FY27 with an around 12% EBITDA margin and plans debt reduction.
The substantial increase in net profit and revenue, coupled with positive outlook and strategic plans for debt reduction and growth, is expected to have a high impact on investor sentiment and the company's stock performance.
The company reported significant year-on-year growth in revenue and net profit, indicating a strong financial performance and positive market reception.
Bodal Chemicals Limited announced its financial results for the second quarter (Q2) and the first half (H1) of FY27. The company reported a significant surge in net profit, with Q2 FY27 consolidated net profit reaching ₹81 crore, a remarkable 1,259% increase year-on-year. Consolidated revenue for Q2 FY27 grew by 77% to ₹884 crore, while EBITDA stood at ₹128 crore, a 197% rise.
For the first half of FY27, consolidated revenue was ₹1,599 crore, up 67% year-on-year, with EBITDA at ₹203 crore, an increase of 114%. Consolidated net profit for H1 FY27 stood at ₹112 crore, compared to ₹16 crore in H1 FY26.
The company highlighted strong performance across its divisions. Dye Intermediates revenue grew by 88% in Q2 FY27 to ₹345 crore, driven by volume and outstanding margins. Dyestuff revenue increased by 60% to ₹212 crore, and Basic Chemicals revenue saw a 199% jump to ₹99 crore in Q2 FY27. The Chlor-Alkali business reported an 8% revenue growth to ₹91 crore in Q2 FY27.
Management expressed optimism, anticipating sustained improvement and contribution from the benzene downstream plant, which is expected to contribute to net profit from the current quarter. The company aims for a FY27 revenue target of over ₹3,000 crore with an EBITDA margin of around 12%. Plans are also in place to reduce debt, with future cash flows primarily allocated to debt repayment, while also exploring growth opportunities through brownfield expansions and potential acquisitions in the ₹100-200 crore range.
What to do with a filing like this
Bodal Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bodal Chemicals Limited. Read the original for the full detail.